Restricted accessResearch articleFirst published online 2012-07
High-Dose-Rate Interstitial Brachytherapy in Early Stage Buccal Mucosa and Lip Cancer: Report on the Consecutive 12 Patients and Review of the Literature
To evaluate clinical outcome and toxicity using high-dose-rate brachytherapy as monotherapy in head and neck carcinomas.
Methods
Between September 2004 and April 2010, a series of 12 patients with lip (7 patients) or buccal mucosa (5 patients) cancers were treated by exclusive interstitial high-dose-rate brachytherapy. The median age of the patients was 71.5 years (range, 47–87). Stages were T1N0M0 and T2N0M0 in 6 and 6 patients, respectively. A dose of 27 to 54 Gy in 9 to 16 fractions, 3 to 4.5 Gy per fraction, 2 fractions per day with a minimal gap of 6 h in between was delivered.
Results
After a median follow-up of 46 months (range, 10–85), the disease-free and overall survival was 83% (10 of 12 patients) and 50% (6 of 12 patients), respectively. The crude local control in the lip cancer patients was 100% and in the buccal mucosa cancer patients was 60%. No severe toxicity was registered.
Conclusions
High-dose-rate brachytherapy is feasible and safe and offers the possibility to treat patients in an outpatient regimen.
GreenleeR.T., MurrayT., BoldenS., WingoP.A.: Cancer Statistics, 2000.CA Cancer J Clin, 50: 7–33, 2000.
2.
ChenA.Y., MyersJ.N.: Cancer of the oral cavity.Dis Mon, 47: 275–361, 2001.
3.
WeberR.S., PalmerJ.M., el-NaggarA., McNeeseM.D., GuillamondeguiO.M., ByersR.M.: Minor salivary gland tumors of the lip and buccal mucosa.Laryngoscope, 99: 6–9, 1989.
4.
MazeronJ.J., NoëlG., SimonJ.M.: Head and neck brachytherapy.Semin Radiat Oncol, 12: 95–108, 2002.
5.
FerlayJ., BrayF., PisaniP., ParkinD.M.: GLOBOCAN 2002 Cancer Incidence, Mortality and Prevalence Worldwide. IARC Cancer Base No. 5, version 2.0 IARC Press, Lyon, 2004.
6.
ReibelJ.: Prognosis of oral pre-malignant lesions: significance of clinical, histopathological, and molecular biological characteristics.Crit Rev Oral Biol Med, 14: 47–62, 2003.
7.
PalmeC.E., GullaneP.J., GilbertR.W.: Current treatment options in squamous cell carcinoma of the oral cavity.Surg Oncol Clin N Am, 13: 47–70, 2004.
8.
CerezoL., LiuF.F., TsangR., PayneD.: Squamous cell carcinoma of the lip: analysis of the Princess Margaret Hospital experience.Radiother Oncol, 28: 142–147, 1993.
9.
de VisscherJ.G., GrondA.J., BotkeG., van der WaalI.: Results of radiotherapy for squamous cell carcinoma of the vermilion border of the lower lip. A retrospective analysis of 108 patients.Radiother Oncol, 39: 9–14, 1996.
10.
de VisscherJ.G., van den ElsakerK., GrondA.J., van der WalJ.E., van der WaalI.: Surgical treatment of squamous cell carcinoma of the lower lip: evaluation of long-term results and prognostic factors — a retrospective analysis of 184 patients.J Oral Maxillofac Surg, 56: 814–820, 1998.
11.
de VisscherJ.G., BotkeG., SchakenraadJ.A., van der WaalI.: A comparison of results after radiotherapy and surgery for stage I squamous cell carcinoma of the lower lip.Head Neck, 21: 526–530, 1999.
12.
NijdamW.M., LevendagP.C., NoeverI., SchmitzP.I., Uyl-de GrootC.A.: Longitudinal changes in quality of life and costs in long-term survivors of tumors of the oropharynx treated with brachytherapy or surgery.Brachytherapy, 7: 343–350, 2008.
13.
MazeronJ.J., ArdietJ.M., Haie-MéderC., KovácsC., LevendagP., PeiffertD., PoloA., RovirosaA., StrnadV.: GEC-ESTRO recommendations for brachytherapy for head and neck squamous cell carcinomas.Radiother Oncol, 91: 150–156, 2009.
14.
PernotM., AlettiP., CarolusJ.M., MarquisI., HoffstetterS., MaaloulF., PeiffertD., LapeyreM., LuporsiE., MarchalC., NoëlA., BeyP.: Indications, techniques and results of postoperative brachytherapy in cancer of the oral cavity.Radiother Oncol, 35: 186–192, 1995.
15.
MazeronJ.J., GerbauletA., SimonJ.M., HardimanC.: How to optimize therapeutic ratio in brachytherapy of head and neck squamous cell carcinoma?Acta Oncol, 37: 583–591, 1998.
16.
LapeyreM., HoffstetterS., PeiffertD., GuérifS., MaireF., DolivetG., ToussaintB., MundtA., ChassagneJ.F., SimonC., BeyP.: Postoperative brachytherapy alone for T1–T2 N0 squamous cell carcinomas of the oral tongue and floor of mouth with close or positive margins.Int J Radiat Oncol Biol Phys, 48: 37–42, 2000.
17.
KolotasC., ZamboglouN.: Role of interstitial brachytherapy in the treatment of malignant disease.Onkologie, 24: 222–228, 2001.
18.
GerbauletA., Van LimbergenE.: Lip cancer. In: GerbauletA., PötterR., MazeronJ.J., MeertensH., Van LimbergenE. (Eds) The GEC ESTRO Handbook of Brachytherapy, Leuven: ESTRO, pp 227–236, 2002.
19.
GerbauletA.: Buccal mucosa cancer. In: GerbauletA., PötterR., MazeronJ.J., MeertensH., Van LimbergenE. (Eds), The GEC ESTRO Handbook of Brachytherapy, Leuven: ESTRO, pp 265–273, 2002.
20.
MazeronJ.J., NoëlG., SimonJ.M., RacadotS., JauffretE.: Brachytherapy in head and neck cancers.Cancer Radiother, 7: 62–72, 2003.
21.
PellizzonA.C., dos Santos NovaesP.E., Conte MaiaM.A., FerrignoR., FogarolliR., SalvajoliJ.V., KowalskiL.P.: Interstitial high-dose-rate brachytherapy combined with cervical dissection on head and neck cancer.Head Neck, 27: 1035–1041, 2005.
22.
PeiffertD., CastelainB., ThomasL., ArdietJ.M., BailletF., MazeronJ.J.: Pulsed dose rate brachytherapy in head and neck cancers. Feasibility study of a French cooperative group.Radiother Oncol, 58: 71–75, 2001.
23.
KoedooderK., van WieringenN., van der GrientH.N., van HertenY.R., PietersB.R., BlankL.E.: Safety aspects of pulsed dose rate brachytherapy: analysis of errors in 1,300 treatment sessions.Int J Radiat Oncol Biol Phys, 70: 953–960, 2008.
24.
FriedrichR.E., KrüllA., HellnerD., SchwarzR., HeyerD., PlambeckK., SchmelzleR.: Interstitial high-dose rate brachytherapy with iridium-192 in patients with oral squamous cell carcinoma.J Craniomaxillofac Surg, 23: 238–242, 1995.
25.
DonathD., VuongT., ShenoudaG., MacDonaldB., TabahR.: The potential uses of high-dose-rate brachytherapy in patients with head and neck cancer.Eur Arch Otorhinolaryngol, 252: 321–324, 1995.
26.
YodenE., HiratsukaJ., ImajoY., HataT., HosodaM.: High dose rate microselectron mould radiotherapy of a widespread superficial oral cancer.Int J Oral Maxillofac Surg, 28: 451–453, 1999.
27.
RudoltzM.S., PerkinsR.S., LuthmannR.W., FrackeT.D., GreenT.M., MoyeL., WludykaP., ChoiY.K., AckermanS.N.: High-dose-rate brachytherapy for primary carcinomas of the oral cavity and oropharynx.Laryngoscope, 109: 1967–1973, 1999.
28.
ArijiE., HayashiN., KimuraY., UchidaT., HayashiK., NakamuraT.: Customized mold brachytherapy for oral carcinomas through use of high-dose-rate remote afterloading apparatus.Oral Surg Oral Med Pathol Oral Radiol Endod, 87: 508–512, 1999.
29.
GuinotJ.L., ArribasL., ChustM.L., MengualJ.L., García Mira-gallE., CarrascosaM., EscolarP.P., CrispínV., GuardinoC.: Lip cancer treatment with high dose rate brachytherapy.Radiother Oncol, 69: 113–115, 2003.
30.
JainS.K., KumarA., SinghJ.K.: HDR brachytherapy with external beam radiotherapy in node negative early stage oral cavity cancer.JCO, 22: 5553 (abstract), 2004.
31.
PrisciandaroJ.I., FooteR.L., HermanM.G., LeeS.J., LaJoieW.N., Van BlarcomA.B., YeakelP.D.: A buccal mucosa carcinoma treated with high dose rate brachytherapy.J Appl Clin Med Phys, 6: 8–12, 2005.
32.
Finestres-ZubeldiaF., Guix-MelciorB., Cloquell-DamianA., Chimenos-KüstnerE., Tello-LuqueJ.I.: Treatment of the carcinoma of the lip through high dose rate brachytherapy.Med Oral Patol Oral Cir Bucal, 10: 21–24, 2005.
33.
PeteraJ., DolezelM., JirousekZ., TucekL., BedrosovaJ., FrgalaT.: High dose rate brachytherapy in the treatment of oral cancer — the preliminary one institution experience.Neoplasma, 53: 232–236, 2006.
34.
JhaA.K., PrasikoG., ModM., SrivastavaR., ChaurasiaP.P.: Curative interstitial brachytherapy for early stage carcinoma lip.J Nepal Med Assoc, 45: 252–257, 2006.
35.
LapeyreM., BellièreA., HoffstetterS., PeiffertD.: Brachytherapy for head and neck cancers (nasopharynx excluded).Cancer Radiother, 12: 515–521, 2008.
36.
NagS., CanoE.R., DemanesD.J., PuthawalaA.A., VikramB.: The American Brachytherapy Society recommendations for high-dose-rate brachytherapy for head-and-neck carcinoma.Int J Radiat Oncol Biol Phys, 50: 1190–1198, 2001.
37.
UICC TNM:Classification of Malignant Tumours, 6th Edition.New York: Wiley Liss2002.
38.
PierquinB., DutreixA., PaineC.H., ChassagneD., MarinelloG., AshD.: The Paris system in interstitial radiation therapy.Acta Radiol Oncol, 17: 33–48, 1978.
39.
LevendagP.C., VischL.L., DriverN.: A simple device to protect against osteoradionecrosis induced by interstitial irradiation.J Prosthet Dent, 63: 665–670, 1990.
40.
LozzaL., CerrottaA., GardaniG., De MarieM., Di RussoA., KendaR., TanaS., ValvoF., ZucaliR.Analysis of risk factors for mandibular bone radionecrosis after exclusive low dose-rate brachytherapy for oral cancer.Radiother Oncol, 44: 143–147, 1997.
CoxJ.D., StetzJ., PajakT.F.: Toxicity criteria of the Radiation Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC).Int J Radiat Oncol Biol Phys, 31: 1341–1346, 1995.
45.
ZurridaS., BartoliC., BonoA., ChiesaF.: Outpatient surgical treatment of lip carcinomas: immediate and long-term results.Tumori, 75: 263–265, 1989.
46.
HarrisonL.B.: Applications of brachytherapy in head and neck cancer.Semin Surg Oncol, 13: 177–184, 1997.
StrnadV.: Treatment of oral cavity and oropharyngeal cancer. Indications, technical aspects, and results of interstitial brachytherapy.Strahlenther Onkol, 180: 710–717, 2004.
49.
OrecchiaR., RampinoM., GribaudoS., NegriG.L.: Interstitial brachytherapy for carcinomas of the lower lip. Results of treatment.Tumori, 77: 336–338, 1991.
50.
CerezoL., LiuF.F., TsangR., PayneD.: Squamous cell carcinoma of the lip: analysis of the Princess Margaret Hospital experience.Radiother Oncol, 28: 142–147, 1993.
51.
BeauvoisS., HoffstetterS., PeiffertD., LuporsiE., CarolusJ.M., DartoisD., PernotM.: Brachytherapy for lower lip epidermoid cancer: tumoral and treatment factors influencing recurrences and complications.Radiother Oncol, 33: 195–203, 1994.
52.
FongioneS., SignorM., BeorchiaA.: Interstitial brachytherapy in carcinoma of the lip. Case histories and results.Radiol Med, 88: 657–660, 1994.
53.
FarrusB., PonsF., Sanchez-ReyesA., FerrerF., RovirosaA., BieteA.: Quality assurance of interstitial brachytherapy technique in lip cancer: comparison of actual performance with the Paris System recommendations.Radiother Oncol, 8: 145–151, 1996.
54.
TomboliniV., BonanniA., ValerianiM., ZurloA., VitturiniA.: Brachytherapy for squamous cell carcinoma of the lip. The experience of the Institute of Radiology of the University of Rome ‘La Sapienza’.Tumori, 84: 478–482, 1998.
55.
GrabenbauerG.G., RödelC., BrunnerT., Schulze-MosgauS., StrnadV., MüllerR.G., IroH., SauerR.: Interstitial brachytherapy with Ir-192 low-dose-rate in the treatment of primary and recurrent cancer of the oral cavity and oropharynx. Review of 318 patients treated between 1985 and 1997.Strahlenther Onkol, 177: 338–344, 2001.
56.
MohantiB.K., BansalM., BahadurS., ShuklaN.K., DeoS.V., PrabhakarR., RathG.K.: Interstitial brachytherapy with or without external beam irradiation in head and neck cancer: Institute Rotary Cancer Hospital experience.Clin Oncol, 13: 345–352, 2001.
57.
AslayI., KüçücükS., KemiklerG., KurulS., HafizG., OzbayI., DisçiR., KizirA., TöreG.: Effectiveness of brachytherapy in the treatment of lip cancer: a retrospective study at the Istanbul University Oncology Institute.Adv Ther, 22: 395–406, 2005.
58.
NganR.K., WongR.K., TangF.N., TangD.L.: Curative radiotherapy for early cancers of the lip, buccal mucosa, and nose – a simple interstitial brachytherapy technique employing angiocatheters as carriers for iridium-192 wire implants.Hong Kong Med J, 11: 351–359, 2005.
LockM., CaoJ.Q., D'SouzaD.P., HammondaJ.A., KarnasS., LewisC., VenkatesanV.M., WhistonE., YauG., YuE., GilchristJ., RodriguesG.B.: Brachytherapy with permanent gold grain seeds for squamous cell carcinoma of the lip.Radiother Oncol, 98: 352–356, 2011.
62.
GuibertM., DavidI., VergezS., RivesM., FilleronT., BonnetJ., DelannesM.: Brachytherapy in lip carcinoma: long term results.Int J Radiat Oncol Biol Phys, 81: e839–843, 2011.
63.
StrnadV., MelznerW., GeigerM., ZenkJ., WaldfahrerF., LotterM., OttO., SeegerA., IroH., SauerR.: Role of interstitial pulsed-dose-rate brachytherapy in the treatment of oral and oropharyngeal cancer. A single-institute experience of 236 patients.Strahl Onkol, 181: 762–767, 2005.
64.
GerbauletA., PernotM.: Le carcinome epidermoide de la face interne de joue: a propos de 748 malades.J Eur Radiother, 6: 1–4, 1985.
65.
ShibuyaH., TakedaM., MatsumotoS., HoshinaM., ShagdarsurenM., SuzukiS.: Brachytherapy for non-metastatic squamous cell carcinoma of the buccal mucosa. An analysis of forty-five cases treated with permanent implants.Acta Oncol, 32: 327–330, 1993.
66.
LapeyreM., PeiffertD., MalissardL., HoffstetterS., PernotM.: An original technique of brachytherapy in the treatment of epidermoid carcinomas of the buccal mucosa.Int J Radiat Oncol Biol Phys, 33: 447–454, 1995.
67.
PernotM., HoffstetterS., PeiffertD., AlettiP., LapeyreM., MarchalC., LuporsiE., BeyP., NancyV.L.: Role of interstitial brachytherapy in oral and oropharyngeal carcinoma: reflection of a series of 1344 patients treated at the time of initial presentation.Otolaryngol Head Neck Surg, 115: 519–526, 1996.
